Who We Are
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. Retisert® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Company’s pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases.
Ms. Lurker has been our President and Chief Executive Officer since September 2016. From 2008 to 2015, Ms. Lurker served as President and Chief Executive Officer and a director of PDI, Inc., a NASDAQ-listed healthcare commercialization company now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation (Pharmacia), now a part of Pfizer, Inc. She also served as a member of Pharmacia’s U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker serves as chair of the board of directors of X4 Pharmaceuticals, Inc. and as a member of the board of directors of the Cancer Treatment Centers of America, both privately held companies. Ms. Lurker previously served as a member of the boards of directors of publicly held Auxilium Pharmaceuticals, Inc. from 2011 to 2015 and Mallinckrodt Pharmaceuticals, plc from 2013 to 2016, in addition to serving as a director of PDI, Inc. from 2008 to 2015. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. We believe Ms. Lurker is qualified to serve on our Board because of her role as our President and Chief Executive Officer, as well as her broad ranging experience in the pharmaceutical industry and her track record of maximizing the potential of new therapies and successfully implementing innovative U.S. and global drug launches, which provide her with valuable expertise and perspective on our corporate strategy, management, operations and governance.
Tom Hadley has served as Vice President of Marketing and Sales at EyePoint since March of 2018. Mr. Hadley brings to EyePoint more than 25 years of successful experience in driving organizational value. He has extensive experience in preparing and executing on highly successful commercial pharmaceutical launches across multiple therapeutic areas, both in the US and Globally.
Prior to joining EyePoint, Mr. Hadley served as the GVP, General Manager at Horizon Pharmaceuticals where he led a team of more than 350 across marketing and sales and delivered over $2B in topline revenue for the portfolio of DUEXIS®(ibuprofen and famotidine), VIMOVO®(naproxen/esomeprazole magnesium), and PENNSAID2%®(diclofenac sodium topical solution). Prior to Horizon, Mr. Hadley was Head of Marketing for the Salix business unit of Bausch Health (formerly Valeant), where he launched Xifaxin®(rifaximin) for IBS-D and delivered over $1.5B in topline revenue across multiple product lines. While at Bausch he also served as Head of Marketing for Dermatology where he led the successful launches of Jublia®(efinaconazole) and Luzu®(luliconazole).
In 2016 he was recognized as an Elite 100 for Launch Excellence by PM360. Mr. Hadley received his BS in Marketing from Seton Hall University.
Ron Honig has served as EyePoint’s Senior Vice President, General Counsel and Company Secretary since November 2018. Mr. Honig brings to EyePoint more than 25 years of legal experience in the medical device, biotechnology, contract manufacturing and legal services industries. He has extensive experience in global medical technology transactions, mergers and acquisitions, and oversight of legal and compliance functions for public and private companies.
Most recently, Mr. Honig served as VP, Global Legal Affairs for Novanta Inc., a publicly-traded company that develops and manufactures technology solutions for medical device and advanced industrial equipment makers worldwide. Prior to Novanta, he was the Senior Vice President, General Counsel & Company Secretary of Lake Region Medical, a privately-held medical device and medical component manufacturer, where he was responsible for all legal, intellectual property and environmental, health and safety functions worldwide. In addition, Mr. Honig served as Vice President, Group Legal Affairs and Company Secretary for Gyrus ACMI, a publicly-traded medical device manufacturer focused on urological and gynecological endoscopes, digital visualization and endoscopic treatment and delivery modalities.
In addition to his in-house legal experience, Mr. Honig previously served as a corporate attorney for several law firms, including Mintz Levin Cohn Ferris Glovsky and Popeo in Boston. He earned his Juris Doctor degree from Boston University, where he served as Editor-In-Chief of the Boston University Law Review, and earned a Bachelor of Science in Finance from the Wharton School and a Bachelor of Applied Science in Systems Engineering from the School of Engineering at the University of Pennsylvania.
Mr. Jones brings to EyePoint significant experience commercializing drugs and devices globally. Most recently, he served as Chief Commercial Officer and Vice President, Business Development at Notal Vision, where he developed the commercial and growth strategy for the organization. Mr. Jones’ tenure at Notal Vision also included his role as President, in which he was responsible for developing a business model in the United States that would allow for a telemonitoring platform to be covered by Medicare. Before joining Notal Vision, Mr. Jones served as President of QLT Ophthalmics, where he built the strategy and infrastructure for a U.S. commercial operation. Prior to that, Mr. Jones was Executive Director, Health Policy at Novartis Pharmaceuticals, where his team was responsible for all policy issues relating to Medicare Part A, Part B and the Durable Medical Equipment Program. Mr. Jones also served as Executive Director and Head of Market Access and Government Affairs at Novartis Ophthalmics, as well as other roles of varying responsibility during his time at Novartis. Mr. Jones began his career with Geigy Pharmaceuticals as Medical Representative and subsequently as Hospital Sales Representative for Ciba-Geigy Pharmaceuticals. Mr. Jones received an M.A. in political science and a Certificate in Public Administration from the University of Florida, as well as a B.S. in chemistry.
Ms. Leonard currently serves as the Senior Vice President of Human Resources and IT. She brings to EyePoint over 25 years of successful executive coaching, organizational effectiveness, leadership development, talent management and culture development experience. Most recently Ms. Leonard served as the Head of HR, Consumer Healthcare and Global Functions for Sanofi, US. From 2012 to 2015, Ms. Leonard served as the Senior Vice President of HR & IT of PDI, Inc., a NASDAQ-listed healthcare commercialization company now named Interpace Diagnostics Group, Inc.
Ms. Leonard has led, managed, mentored and coached individuals and teams to achieve outstanding business results. She has designed and implemented organizational development solutions at companies to increase corporate employee engagement and people effectiveness. She has led numerous M&A activities and resulting culture change and personnel integration activities.
Ms. Leonard’s experiences include work with global companies such as Novartis, Pharmacia/Pfizer, Boston Scientific Corporation, Biovail Pharmaceuticals and Silicon Graphics (SGI). Ms. Leonard also established and developed her own company, ImpactHR, LLC which provided coaching and consulting services to the life sciences sector.
Ms. Leonard holds a Masters Degree in Organizational Development and Human Resources from The University of San Francisco, and a B. A. in Psychology and Business Administration from The University of California at Los Angeles (UCLA.) Ms. Leonard is a Certified Professional Coach and has earned her Associate Certified Coach (ACC) from the International Coaching Federation (ICF.) She is also certified in the Hogan Assessment Certified Consultant.
Dr. Paggiarino joined EyePoint from Lpath, a leader in lipid-targeted therapeutics, where he served as Senior Vice President and Chief Development Officer. Prior to joining Lpath, he was Vice President and Therapeutic Unit Head for Retinal Diseases at Alcon Laboratories, a division of Novartis, where he was responsible for advancing its retina pharmaceutical development pipeline through regulatory approvals worldwide. Dr. Paggiarino previously served as Executive Director of Clinical Development and Medical Affairs at Pfizer Global R&D, with focus on global clinical development in glaucoma, diabetic and degenerative retinal diseases and medical responsibilities for Macugen®, the first anti-VEGF treatment approved for age-related macular degeneration. Earlier in his career he held research and development positions at Angelini Pharmaceuticals, a private company, where he advanced to president of the firm, and Pharmacia Global R&D, where he was Clinical Program Director of Ophthalmology with responsibilities including Xalatan®, one of the leading glaucoma therapies in the world. Dr. Paggiarino earned his degree in Medicine and General Surgery cum laude from the University of Rome La Sapienza and has authored numerous scientific articles.
Dr. Saim has more than 25 years of product development experience. He most recently served as Vice President, Pharmaceutical Development at Collegium Pharmaceutical, where his responsibilities included managing formulation development, clinical trial manufacturing, and commercial manufacturing for immediate, delayed and controlled release dosage forms. Prior to joining Collegium, Dr. Saim served as Senior Principal Scientist at Boehringer Ingelheim Pharmaceuticals, Inc., where he led a team of engineers and scientists in charge of process development, scale up, and technology transfer of North American products. Prior to joining Boehringer Ingelheim, Dr. Saim was Assistant Research Professor at the Higuchi BioSciences Center for Drug Delivery Research. Dr. Saim has published 22 papers in engineering and science journals and holds 18 patents. Dr. Saim earned a Ph.D. in chemical engineering from the University of Kansas.
Jack Weet has served as EyePoint’s Senior Vice President, Regulatory since August 2018. Dr. Weet brings to EyePoint over 40 years of experience in regulatory affairs. He has extensive expertise in the oversight of U.S. Food and Drug Administration relations and negotiations across multiple therapeutic areas, including ocular disease.
Prior to joining EyePoint, Dr. Weet served as Vice President, Regulatory Affairs and Quality Assurance at Collegium Pharmaceutical, a commercial stage specialty pharmaceutical company focused on pain management, where he was responsible for overall regulatory direction and development of standard practices, procedures and regulatory operations, and worked closely on the approval for XTAMPZA® ER, an extended-release, abuse-deterrent opiate. Prior to Collegium, Dr. Weet was Vice President, Regulatory Affairs at Durata Therapeutics (acquired by Actavis plc) and Vertex Pharmaceuticals, where he worked on the regulatory submission of Dalvance® (dalbavancin) and Incivek® (telaprevir), respectively. He also previously served as Vice President, Global Regulatory Affairs at Bausch + Lomb, a wholly owned subsidiary of Bausch Health focused on the treatment and prevention of diseases of the eye, where he oversaw global regulatory affairs for the company’s pharmaceutical business. In this role, Dr. Weet worked on the regulatory submission for Besivance® (besifloxacin) for the treatment of bacterial conjunctivitis. Prior to joining Bausch + Lomb, he served in various regulatory affairs positions at numerous pharmaceutical companies including Biovail Technologies, Ltd., Novartis Pharmaceuticals, and Solvay Pharmaceuticals.
In addition to his industry experience, Dr. Weet has served on the faculty of the Pharmaceutical Education and Research Institute (PERI), as a guest lecturer at Georgia Institute of Technology, a member of the Long Island University Curriculum Planning Committee of the Arnold and Marie Schwartz College of Pharmacy, and has authored various papers and presentations at industry conferences.
Dr. Weet received a B.S. in Psychology from St. Lawrence University, and a Ph.D. in Physiology from the Ohio State University College of Medicine. He completed his postdoctoral fellowship at the University of Iowa College of Medicine.
Dr. Göran Ando has had a distinguished career in the global pharmaceutical industry that has spanned nearly four decades. He began his career at Pfizer, Inc., where he held several senior clinical positions both in the U.S. and in Europe. Dr. Ando also served as President of the Astra Research Centre. He held various senior appointments at GlaxoSmithKline plc, including Research and Development Director for Glaxo Group Research.. Dr. Ando then joined Pharmacia AB in 1995 as Executive Vice President and Deputy Chief Executive Officer to lead Research and Development with additional responsibilities for manufacturing, information technology, business development and M&A. During his nine-year tenure as Head of Research and Development at Pharmacia/Pharmacia & Upjohn, 17 new drugs were approved by the U.S. Food and Drug Administration (FDA) prior to Pharmacia’s acquisition by Pfizer for $60 billion.
Dr. Ando is the retired Chairman of Novo Nordisk A/S and previously served as the Chief Executive Officer of Cell Tech Group PLC. He has also served as Chairman of the Board for several European-based biopharmaceutical companies and he currently serves as a Board member of biopharmaceutical companies in Europe, U.S. and Singapore. He is a Senior Advisor at EW Healthcare Partners. Dr. Ando received his Bachelor of Arts degree from Uppsala University in Sweden and Doctor of Medicine degree from Linköping University in Sweden.
Wendy DiCicco is a veteran healthcare executive with 30 years of financial and corporate development experience. She most recently was Chief Operating and Financial Officer of Centinel Spine, a privately-held designer, developer and worldwide distributor of spinal implants, where she established the Company’s international operations, and was instrumental in both the recapitalization of the Company with $132.5 million in equity and debt and in corporate development initiatives resulting in the purchase of the ProDisc® spinal product and its commercialization in 20 countries. Ms. DiCicco currently serves on the Board of Directors of Carmell Therapeutics, a private biotechnology company producing plasma-based bioactive materials for accelerated healing in bone and connective tissue injuries, and is a Financial, Executive and Board Advisory Consultant for several emerging growth companies. She previously served as President and Chief Operating Officer of Camber Spine Technologies where she significantly expanded the Company’s operations, infrastructure and commercial organization. Prior to Camber Spine, she held several Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Her career started in public accounting at Deloitte & Touche.
Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow and Corporate Governance Fellow of the National Association of Corporate Directors (NACD).
Mr. Eastman led and served on the Board of Directors of EW’s growth equity investment in ProteinSimple (acquired by Bio-Techne). He currently serves on the Board of Directors of EW portfolio companies Elusys, Corium, Suneva and Symphogen.
Mr. Eastman has over 40 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, which was acquired by American Home Products (now Pfizer), where Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Later as CEO of Geron, Mr. Eastman led the company’s growth from a venture-backed start-up to a publicly traded pioneer in the fields of regenerative medicine and cancer. Most recently, at Rinat, a private biotech company spun out of Genentech with the support of EW in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer for $500M in 2006.
Mr. Eastman has a Bachelor of Arts degree from Williams College and a Master of Business Administration degree from Columbia University
Dr. Guyer currently serves as Executive Chairman of Ophthotech Corporation, a publicly-traded biopharmaceutical company specializing in gene therapy treatments for ocular diseases, which he co-founded. Before founding Opthotech, Dr. Guyer served as a partner and venture partner at SV Life Sciences Advisers, a venture capital firm focused on healthcare. Dr. Guyer co-founded Eyetech Pharmaceuticals Inc. and served as its Chief Executive Officer and as a member of its Board of Directors from 2000 until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. Prior to co-founding Eyetech Pharmaceuticals, Dr. Guyer was a Professor and served as Chairman of the Department of Ophthalmology at New York University School of Medicine. He currently serves on the Board of Directors of Oxurion NV, a publicly traded biotechnology company.
Dr. Guyer received a B.S. from Yale College and an M.D. from Johns Hopkins Medical School. Dr. Guyer completed his ophthalmology residency at Wilmer Ophthalmological Institute, Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.
Dr. Landis is currently President of the Board of Exelead, a lipid drug delivery CMO, and serves on the Board of Symphogen, a company developing mixtures of monoclonal antibodies against oncology targets, where he chairs the development committee. He also chairs the Purdue University External Oncology Board, helping the faculty to transition their discoveries to the clinic. He is a current member of Purdue University’s Chemistry Leadership Council for the School of Science.
Dr. Landis earned Ph.D. and M.S. degrees in analytical chemistry from Purdue University and a B.S. degree in chemistry from Kent State University. He was awarded an Honorary Doctor of Science Degree from Purdue University in 2008.
Dr. Mazzo has been the Chief Executive Officer and a director of Caladrius Biosciences, Inc., a Nasdaq Stock Market LLC, or NASDAQ, listed company, since January 2015. Caladrius is a clinical stage development company with a pipeline of cell therapy product candidates in autoimmune disease (type I diabetes) and select cardiovascular indications. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the board of directors of Regado Biosciences, Inc., a NASDAQ-listed biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc., a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Dr. Mazzo has also held senior management and executive positions in research and development and/or directorships with the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the U.S. subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulene SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also previously served on the board of directors of Avanir Pharmaceuticals, Inc., a specialty pharmaceutical company, from 2005 until Avanir was sold to Otsuka Holdings in 2015. Dr. Mazzo earned a B.A. in the Honors Program (Interdisciplinary Humanities) and a B.S. in Chemistry from Villanova University. In addition, Dr. Mazzo received his M.S. in chemistry and his Ph.D. degree in analytical chemistry from the University of Massachusetts, Amherst. He was also a research fellow at the Ecole Polytechnique Federale de Lausanne, Switzerland. We believe Dr. Mazzo is qualified to serve on our Board because his extensive experience as an executive officer and director in the life sciences industry, his understanding of the strategic and regulatory environment in which we conduct our business, his lengthy track record in global product development, his Ph.D. in analytical chemistry and his broad scientific and managerial background provide him expertise in the oversight of companies in this sector and the ability to guide such companies through varying operating climates.
Ms. Peterson has over 30 years of healthcare industry experience. She most recently served from 2009 to 2016 as Chief Executive Officer of Valeritas, Inc., a medical technology company focused on innovative drug delivery systems, and as a strategic advisor to Valeritas until August 2017. Prior to that, Ms. Peterson served as Company Group Chair of Johnson & Johnson’s biotech groups from 2006 to 2009, and as Executive Vice President of Johnson & Johnson’s global strategic marketing organization from 2004 to 2006. Prior to that, she served as Senior Vice President, Commercial Operations for Biovail Corporation, a pharmaceutical company, and President of Biovail Pharmaceuticals from 2003 to 2004. Ms. Peterson began her career at Bristol-Myers Squibb, holding assignments of increasing responsibility spanning marketing, sales and general management, including running a cardiovascular / metabolic business unit and a generics division. Ms. Peterson is also a director of Paratek Pharmaceuticals, Inc., Immunogen, Inc. and Amarin Corporation plc, and within the past five years also served as a director of Valeritas, Inc. Ms. Peterson earned a B.S. and M.B.A. from the University of Illinois at Champaign Urbana. We believe Ms. Peterson is qualified to serve on our Board because of her extensive executive management and sales and marketing experience in both large, multinational pharmaceutical and smaller biotechnology companies, in particular as it relates to later-stage development and commercialization, as well as her other public company board experience.
EyePoint has successfully created partnerships with some of the world’s leading pharmaceutical companies. EyePoint seeks additional strategic partners to collaborate on the development of new sustained-release bioerodible drug devices; to access complementary research, technology and development capabilities; and to expand our product portfolio.
EyePoint’s technologies have broad applicability across many therapeutic areas. Our validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. EyePoint’s intellectual property portfolio consists of our proven DurasertTM Technology platform and our VerisomeTM technology platform.